Autism Disorder and Treatment Market – Overview
The neurological and developmental effects of autism disorder are the core factors promoting the expansion of treatment and diagnostic options for autism. Market reports linked to the healthcare industry have been made available by Market Research Future which creates reports on other industry verticals that outlines the current market scenarios. The market is reportedly poised to achieve a CAGR of 4.37% approximately in the duration of the forecast period.
Latest Free Sample Copy Available @ https://www.marketresearchfuture.com/sample_request/1605
Autism Disorder and Treatment Market Segmentation
The global autism disorder and treatment market segmentation encompasses drugs, type, and treatment type. MRFR’s research on the market highlights many facets of the market in-depth.
Based on drugs, this market has been segmented into anti-convulsant drugs, anti-psychotic drugs, selective serotonin reuptake inhibitors (SSRIs), and stimulants. The antipsychotic drugs segment has been sub-segmented into Abilify (aripiprazole) and risperidone. The antipsychotic drugs segment has the maximum market coverage and is expected to grow at 3.95% CAGR during the forecast period.
By type, the market includes Asperger syndrome, pervasive developmental disorder, and others. During the forecast period, the pervasive developmental disorder is expected to grow at 4.73% CAGR, as it is the largest market segment.
Regarding treatment type, the market has been segmented into the applied behavioral analysis (ABA), chelation therapy, hyperbaric oxygen therapy, oxytocin therapy, and others. ABA is the largest and market segment, and during the forecast period, it is expected to grow at 4.82% CAGR.
Autism Disorder and Treatment Market Regional Segmentation
A geographical outlining of the global Autism Disorder and Treatment Market covers the Americas (North America & South America), Europe, APAC (Asia Pacific), and the Middle East & Africa (MEA).
The Americas region commands the maximum market share in the global market, followed by Europe. The presence of major market players, availability of advanced medical facilities, and technological advancement make North America a bigger market compared to South America. The market in North America is growing due to the approval, and it expects the launch of the atypical anti-psychotic such as Latuda and Namenda, with their high sales in the USA. Many autism cases have been detected in North America. After the USA, Canada generates maximum sales as well as revenue with regards to autism treatment and drugs.
Europe is the second-largest regional market as after North America; maximum major market players are based in Europe. The countries that can become important markets during the forecast period are France, Germany, Italy, Spain, and the UK. Research on the remaining countries in Western Europe featured in this report estimate the strong addition to market revenue from various other countries in this region, with some sizable market revenue from Eastern Europe.
During the forecast period, the market in the Asia Pacific region can be the fastest growing regional market. In this region, the factors contributing to the market growth include the expansion of diagnostic criteria, increasing prevalence of ASD, more awareness, better diagnostic tools, and improved reporting. The countries that can be crucial markets in this region are Australia, China, India, Japan, and South Korea.
During the forecast period, the market in the MEA region can grow steadily due to slow progress in the improvement of healthcare infrastructure. The countries that can be decent markets in this region are Kuwait, Oman, Saudi Arabia, Qatar, and the UAE.
Autism Disorder and Treatment Market Analyzed by Top Key Players
Big players in the global autism disorder and treatment market are Allergan (Ireland), Bristol-Myers Squibb (USA), Consern Pharma Private Limited (India), Coronis Partners Ltd. (Israel), Curemark LLC (USA), Eli Lilly & Company (USA), Heptares Therapeutics Limited (UK), Intra-Cellular Therapies Inc. (USA), Johnson & Johnson Services Inc. (USA), Merck & CO Inc. (USA), Novartis AG (Switzerland), Otsuka Holdings Co. Ltd. (Japan), Pfizer Inc. (USA), Saniona AB (Denmark), and Teva Pharmaceutical Industries Ltd. (Israel).
Latest Industry News
- National Institute of Mental Health has awarded grant worth USD 3.3 Mn to Zylka Lab. The grant was approved based on a study and would be used for a better understanding of a genetic mutation in UBE3A that contributes to certain characteristics of autism. 18 SEP 2019
Read Complete Report @ https://www.marketresearchfuture.com/reports/autism-disorder-and-treatment-market-1605
